Characterization of Risk Factors for Calciphylaxis in Hemodialysis Patients in the Fraser Health Renal Program - A Matched Case-Control Retrospective Review

被引:1
|
作者
Jang, Ashley [1 ]
Ho, Man Hon Mark [2 ]
Yan, Luzhi [3 ]
机构
[1] Burnaby Hosp, Dept Pharm, Burnaby, BC, Canada
[2] Royal Columbian Hosp, Dept Pharm, New Westminster, BC, Canada
[3] Surrey Mem Hosp, Dept Pharm, Surrey, BC, Canada
关键词
nephrology; dialysis; calciphylaxis; risk factors; warfarin; CALCIFIC UREMIC ARTERIOLOPATHY; DISEASE;
D O I
10.1177/08971900221118444
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Calciphylaxis is a lethal and rare disease characterized by ischemic and necrotic skin lesions caused by vascular calcification of adipose tissue. There have been many risk factors analyzed in the literature; however, the pathogenesis of calciphylaxis is still not well understood and treatment options are limited due to the lack of interventional studies. Our objectives were to describe risk factors, prevalence, incidence, and outcomes for calciphylaxis in hemodialysis patients within the Fraser Health Renal Program. Methods This was a retrospective matched case-control study of hemodialysis patients within the Fraser Health Renal Program. Hemodialysis patients with calciphylaxis were matched to hemodialysis patients without calciphylaxis in a 1:2 ratio for age and sex from September 2, 2017 to July 3, 2020. Findings There was a total of 40 calciphylaxis cases matched to 80 controls. In the univariate analysis, peritoneal dialysis, higher body mass index, lower serum iron, lower transferrin saturation, sevelamer, cinacalcet, warfarin, iron (PO), and insulin were associated with increased risk of calciphylaxis. In the multivariate analysis, only peritoneal dialysis, serum iron, sevelamer, and warfarin were identified as significant and strong risk factors associated with calciphylaxis. A low prevalence of 1.9% and high mortality rate of 57.5% at 12 months was found for calciphylaxis cases. Discussion Significant risk factors associated with calciphylaxis were peritoneal dialysis, serum iron, sevelamer, and warfarin. Future studies should further investigate the impact of minimizing exposure to these risk factors to reduce calciphylaxis development.
引用
收藏
页码:1424 / 1437
页数:14
相关论文
共 50 条
  • [1] Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study
    Liu, Yuqiu
    Zhang, Xiaoliang
    Xie, Xiaotong
    Yang, Xin
    Liu, Hong
    Tang, Rining
    Liu, Bicheng
    RENAL FAILURE, 2021, 43 (01) : 406 - 416
  • [2] Risk factors for bloodstream infection in patients at a Brazilian hemodialysis center: a case-control study
    Fram, Dayana
    Pinto Okuno, Meiry Fernanda
    Taminato, Monica
    Ponzio, Vinicius
    Manfredi, Silvia Regina
    Grothe, Cibele
    Belasco, Angelica
    Sesso, Ricardo
    Barbosa, Dulce
    BMC INFECTIOUS DISEASES, 2015, 15
  • [3] A case-control study of calciphylaxis in Japanese end-stage renal disease patients
    Hayashi, Matsuhiko
    Takamatsu, Ichiro
    Kanno, Yoshihiko
    Yoshida, Tadashi
    Abe, Takayuki
    Sato, Yuji
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (04) : 1580 - 1584
  • [4] Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study
    Raphaël Gaisne
    Morgane Péré
    Victorio Menoyo
    Maryvonne Hourmant
    David Larmet-Burgeot
    BMC Nephrology, 21
  • [5] Risk factors for candidemia: a prospective matched case-control study
    Julien Poissy
    Lauro Damonti
    Anne Bignon
    Nina Khanna
    Matthias Von Kietzell
    Katia Boggian
    Dionysios Neofytos
    Fanny Vuotto
    Valérie Coiteux
    Florent Artru
    Stephan Zimmerli
    Jean-Luc Pagani
    Thierry Calandra
    Boualem Sendid
    Daniel Poulain
    Christian van Delden
    Frédéric Lamoth
    Oscar Marchetti
    Pierre-Yves Bochud
    Critical Care, 24
  • [6] Risk factors for candidemia: a prospective matched case-control study
    Poissy, Julien
    Damonti, Lauro
    Bignon, Anne
    Khanna, Nina
    Von Kietzell, Matthias
    Boggian, Katia
    Neofytos, Dionysios
    Vuotto, Fanny
    Coiteux, Valerie
    Artru, Florent
    Zimmerli, Stephan
    Pagani, Jean-Luc
    Calandra, Thierry
    Sendid, Boualem
    Poulain, Daniel
    van Delden, Christian
    Lamoth, Frederic
    Marchetti, Oscar
    Bochud, Pierre-Yves
    CRITICAL CARE, 2020, 24 (01):
  • [7] Calciphylaxis epidemiology, risk factors, treatment and survival among French updates chronic kidney disease patients: a case-control study
    Gaisne, Raphael
    Pere, Morgane
    Menoyo, Victorio
    Hourmant, Maryvonne
    Larmet-Burgeot, David
    BMC NEPHROLOGY, 2020, 21 (01)
  • [8] RISK FACTORS FOR ACUTE MESENTERIC ISCHEMIA IN CRITICALLY ILL BURNS PATIENTS-A MATCHED CASE-CONTROL STUDY
    Soussi, Sabri
    Taccori, Marina
    De Tymowski, Christian
    Depret, Francois
    Chaussard, Maite
    Fratani, Alexandre
    Jully, Marion
    Cupaciu, Alexandru
    Ferry, Axelle
    Benyamina, Mourad
    Serror, Kevin
    Boccara, David
    Chaouat, Marc
    Mimoun, Maurice
    Cattan, Pierre
    Zagdanski, Anne-Marie
    Anstey, James
    Mebazaa, Alexandre
    Legrand, Matthieu
    SHOCK, 2019, 51 (02): : 153 - 160
  • [9] Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease A Case-Control Study
    Dobry, Allison S.
    Ko, Lauren N.
    St John, Jessica
    Sloan, J. Mark
    Nigwekar, Sagar
    Kroshinsky, Daniela
    JAMA DERMATOLOGY, 2018, 154 (02) : 182 - 187
  • [10] Risk factors of idiopathic pulmonary fibrosis in Pakistani population: A matched case-control study
    Zubairi, Ali Bin Sarwar
    Rabbani, Unaib
    Hassan, Maryam
    Fatmi, Zafar
    Ahmed, Naseem
    Ali, Akbar Shoukat
    Rizvi, Nadeem
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (09) : 1782 - 1787